A study to compare the effectiveness of Alpecin liquid & Minoxdil 5% in the management of male pattern baldness(Hair loss).
- Conditions
- Health Condition 1: null- Androgenetic Alopecia
- Registration Number
- CTRI/2014/07/004768
- Lead Sponsor
- Fullife Healthcare Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 210
1.Males aged between 18-55 years
2.Balding stage of III-V on the Hamilton scale and use of global photography to confirm the Hamilton-Norwood stage of balding
3.At least 20% telogen ratio in trichogram
4.Willingness to participate and signing the informed consent form
1.Diagnosed with pathologic forms of alopecia like alopecia areata, trichotillomania, scarring alopecia, drug based alopecia
2.Diagnosed with dermatologic conditions like eczema, fungal scalp infections, seborrheic dermatitis, recurrent herpes, pityriasis versicolor, psoriasis, pigmentary disorders (vitiligo, chloasma), chronic lupus erythematous
3.History of chemotherapy
4.Known hypersensitivity to Mx-5 or any excipients of Alpecin that could interfere directly/indirectly with the study
5.Use of any anti-hair loss treatment within the last 6 months prior to the screening visit
6.Participation in another trial of an investigational product within 28 days prior to the screening visit
7.Any other clinically significant medical condition e.g. active infections, cardiac, psychiatric, neurological, pulmonary, immunological conditions, or hypertension etc. which may, in the judgment of the investigator, interfere with the subjectâ??s ability to participate in the study.
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in anagen rate (AR) (%) from baseline to 6 months (EOS) using frontal and occipital trichogram.Timepoint: from baseline to 6 months (EOS)
- Secondary Outcome Measures
Name Time Method